Circular RNA ADAM9 facilitates the malignant behaviours of pancreatic cancer by sponging miR-217 and upregulating PRSS3 expression
Source abstract
Abstract
Pancreatic cancer (PC) is a highly lethal human cancer. We previously found that Serine protease 3 (PRSS3), as an oncogene, is significantly upregulated in PC. In this study, we aimed to investigate the potential mechanism of PRSS3 dysregulation in PC. In this research, low miR-217 and high circ-ADAM9 expression were found in PC tissues and cell lines, which was closely associated with advanced clinical stage and lymph node metastasis. Patients with low miR-217 or high circ-ADAM9 expression had shorter survival time than those with high miR-217 or low circ-ADAM9 expression. Functionally, manipulation of miR-217 and circ-ADAM9 expression showed opposite effects on cell proliferation, migration and invasion. Stepwise mechanism studies indicated that circ-ADAM9 alleviated the inhibitory effect of miR-217 on PRSS3 by directly sponging miR-217 to increase the expression level of PRSS3, resulting in the activation of ERK/VEGF signalling pathway. In vivo, circ-ADAM9 silencing or miR-217 overexpression evidently retarded the growth of tumour, and the combination of them exhibited an additive inhibitory effect on tumourigenicity. Briefly, the ceRNA regulatory network of circ-ADAM9/miR-217/PRSS3 plays a pivotal role in PC progression by the regulation of ERK/VEGF signalling pathway.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Circular RNAs in diseases · MicroRNA in disease regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pathology, The First Affiliated Hospital of Zhengzhou University
Department of Pathology, School of Basic Medical Sciences, Zhengzhou University
College of Public Health, Zhengzhou University
Institute of Medical and Pharmaceutical Sciences, Zhengzhou University
References (32)
Show source-provided references
1. 10.1016/S0140-6736(16)00141-010.1016/S0140-6736(16)00141-0 ↗
2. 10.1038/s41575-019-0109-y10.1038/s41575-019-0109-y ↗
3. 10.1038/s41571-018-0112-110.1038/s41571-018-0112-1 ↗
4. 10.7150/jca.2693610.7150/jca.26936 ↗
5. 10.1093/nar/18.6.163110.1093/nar/18.6.1631 ↗
6. 10.1007/s00109-017-1578-510.1007/s00109-017-1578-5 ↗
7. 10.1002/mc.2012510.1002/mc.20125 ↗
8. 10.1016/j.ygyno.2015.02.02210.1016/j.ygyno.2015.02.022 ↗
9. 10.18632/oncotarget.1559010.18632/oncotarget.15590 ↗
10. 10.1136/gut.2009.20010510.1136/gut.2009.200105 ↗
11. 10.1016/j.molcel.2018.06.03410.1016/j.molcel.2018.06.034 ↗
12. 10.1016/0092-8674(91)90244-S10.1016/0092-8674(91)90244-S ↗
13. 10.1038/onc.2017.36110.1038/onc.2017.361 ↗
14. 10.7150/jca.2456610.7150/jca.24566 ↗
15. 10.1186/s12943-018-0827-810.1186/s12943-018-0827-8 ↗
16. 10.1038/s41419-018-0454-810.1038/s41419-018-0454-8 ↗
17. 10.1002/jcp.2760110.1002/jcp.27601 ↗
18. 10.1002/hep.2927010.1002/hep.29270 ↗
19. 10.1002/1878-0261.1246810.1002/1878-0261.12468 ↗
20. 10.1158/1541-7786.MCR-12-031410.1158/1541-7786.MCR-12-0314 ↗
21. 10.1038/aja.2013.1410.1038/aja.2013.14 ↗
22. 10.1002/jcp.2748610.1002/jcp.27486 ↗
23. 10.1016/j.lfs.2018.12.02410.1016/j.lfs.2018.12.024 ↗
24. 10.1002/jcp.2739410.1002/jcp.27394 ↗
25. 10.1111/jcmm.1385610.1111/jcmm.13856 ↗
26. 10.1038/s41388-018-0175-610.1038/s41388-018-0175-6 ↗
27. 10.1038/cddis.2017.18110.1038/cddis.2017.181 ↗
28. 10.1038/modpathol.2017.3510.1038/modpathol.2017.35 ↗
29. 10.3233/CBM-17093610.3233/CBM-170936 ↗
30. 10.1371/journal.pone.017639510.1371/journal.pone.0176395 ↗
31. 10.1186/s12943-018-0934-610.1186/s12943-018-0934-6 ↗
32. 10.1002/jcp.2794110.1002/jcp.27941 ↗